Monday, November 16, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
News articleYahoo Finance· May 13, 2026

PDS Biotechnology Q1 2026 Earnings Call: Complete Transcript

View original at finance.yahoo.com
“PDS Biotechnology reported a net loss of $7.3 million for Q1 2026, an improvement from $8.5 million in Q1 2025... Mr. Bozgaard will review the financial results for the quarter ended March 31, 2026.”
Verbatim excerpt from the source · Yahoo Finance · short snapshot: read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • PDS Biotechnology reported a net loss of $7.3 million for Q1 2026

    60% confidence
  • Positive results from PDS01 ADC trials in prostate and colorectal cancer support its potential across multiple solid tumor types

    60% confidence
  • New patents for PDS0101 in the US and Japan extend market protection into the 2040s

    60% confidence
  • Q1 2026 net loss of $7.3 million represents an improvement from the $8.5 million net loss in Q1 2025

    60% confidence
  • During this call, forward-looking statements are being made which are subject to various risks and uncertainties that could cause actual results to differ materially

    60% confidence
  • Management is focusing on advancing PDS0101 as a treatment for HPV 16 positive cancers, with late-stage trials in collaboration with key institutions

    60% confidence
  • The year-over-year improvement in net loss was driven by reduced research and development and general administrative expenses

    60% confidence
  • The amendment of the VERSATILE-003 trial to include progression-free survival as a primary endpoint potentially reduces trial duration and costs

    60% confidence

Cited in these Via News reports

PDS Biotechnology Q1 2026 Earnings Call: Complete Transcript: Source | Via News | finance.via.news